SHINE Medical Technologies, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare announced today the production of patient-dose quantities of the therapeutic isotope lutetium-177 (Lu-177).

According to a release, Lu-177 is used to treat neuroendocrine cancers and has shown promise for the treatment of metastatic prostate and other cancers. The isotope passed GE Healthcare’s quality control testing, including internationally recognized radionuclide purity standards.

“The delivery of patient dose quantities of Lu-177 to GE Healthcare is a significant step forward for SHINE Therapeutics,” SHINE Therapeutics Vice President and General Manager Katrina Pitas said in a statement. “We look forward to continuing to work with GE Healthcare to move Lu-177 closer to commercialization and the patients who will benefit from it most.”

As previously reported, SHINE entered into an agreement with IOCB Prague in May 2019.